Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Houma-Bayou Cane-Thibodaux, LA MSA — September 2026
Houma's tight labor market masks a life sciences talent desert.
Terrebonne and Lafourche parishes sit at 4.1% unemployment and 6.69 candidates per job opening, but Louisiana's generic pharma manufacturing workforce has shrunk to just 79 workers — confirming local hiring can't substitute for CRO/CDMO strategy.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Terrebonne/Lafourche unemployment: 4.1% — May 2026, among Louisiana's lowest parish rates
- Houma RLMA candidates per opening: 6.69 — 1,542 postings vs 13,310 active candidates, Feb 2026
- LA generic pharma manufacturing jobs: 79 workers — Declining 10.4% annually statewide
- VP Regulatory Affairs base pay (national): $320K-$580K — Reflects acute national regulatory scarcity
Key takeaways
Houma's labor market is tight, but not for the roles you need.
Parish-level unemployment at 4.1% and a 6.69-candidate-per-opening ratio reflect energy, healthcare, and government hiring pressure, not life sciences scarcity. Benchmarking local compensation against overall metro tightness risks mispricing specialized scientific and regulatory roles that draw from a national, not regional, candidate pool.
Louisiana's manufacturing base offers no local anchor for CMC builds.
Generic pharmaceutical manufacturing employment in Louisiana sits at just 79 workers and is shrinking 10.4% annually, confirming the state lacks the infrastructure for internal biologics or drug-product manufacturing scale-up. CDMO partnerships remain the structurally logical path for Houma-area employers weighing manufacturing headcount investment.
National regulatory affairs scarcity will hit Houma-based searches harder.
Director-level clinical-stage talent is taking 10-16 weeks to fill nationally, and VP Regulatory Affairs compensation now ranges $320K-$580K for candidates with first-in-class BLA/NDA experience. Without a regional talent base to draw from, Houma employers competing for these roles are effectively bidding in the national market with none of the local supply cushion.
Selective hiring elsewhere in biopharma doesn't mean easier sourcing here.
National layoffs (BioMarin, Bristol Myers) are concentrated in consolidation functions while 64% of biopharma organizations continue active recruiting, meaning displaced talent isn't necessarily regulatory, CMC, or clinical operations talent. Houma-area leaders should not assume September layoff headlines translate into a deeper local or remote-hire candidate pool for execution-critical roles.
Median advertised pay by role — Houma-Bayou Cane-Thibodaux, LA MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $82,152 | $132,964 | $150,000 | Significant increase | $131,354 |
| Clinical Research Associate * | $73,458 | $97,646 | $101,465 | Significant increase | $90,956 |
| Lab Technician * | $39,780 | $45,760 | $51,465 | Moderate decline | $47,402 |
| Regulatory Affairs Specialist * | $72,732 | $98,612 | $116,373 | Moderate decline | $104,000 |
| Clinical Data Manager * | $96,750 | $127,578 | $142,800 | Moderate decline | $123,031 |
| Biostatistician * | $107,702 | $128,494 | $155,013 | Stable | $133,322 |
| Validation Engineer * | $97,024 | $165,360 | $172,800 | Significant increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Houma MSA unemployment held near 4.1% through spring 2026 across both Terrebonne and Lafourche parishes, among the tightest in Louisiana, while the Houma Regional Labor Market Area showed just 6.69 candidates per open job posting in its most recent read — a labor pool stretched thin before life sciences employers even enter the bidding. Offshore energy services, healthcare, and government continue to anchor local wage-setting, meaning any biotech, pharma, or device employer recruiting locally competes against sectors with established, well-funded pay structures rather than a dedicated life sciences labor pool.
What it means
Thin local candidate density and the near-absence of generic pharmaceutical manufacturing employment in Louisiana (79 workers statewide, declining) confirm that build-vs-outsource decisions in this metro tilt structurally toward CRO/CDMO partnerships rather than local hires for specialized R&D, clinical, or manufacturing roles. Any regulatory, quality, or CMC headcount leaders do try to fill locally will face national-level scarcity pricing — director-level clinical operations and CMC roles command $210K–$520K nationally — layered on top of a metro labor market with minimal benchmarking infrastructure for these functions. Consider reviewing whether critical regulatory and CMC roles are better resourced through remote or hybrid hires drawing on coastal compensation data, rather than anchoring offers to local parish wage figures that reflect energy and healthcare labor markets, not life sciences talent.
Looking ahead
Worth watching: October 20 BLS release of September Louisiana unemployment data will clarify whether the 4.2%-4.5% statewide range is stabilizing or drifting upward, informing whether broader labor tightness is easing enough to support new local hiring pushes.
Emerging pressure point: Continued 15-20% year-over-year growth in national life sciences job postings suggests regulatory and manufacturing talent will keep tightening through Q4, raising the relative cost of any Houma-based or remote specialist search launched this quarter.
Early indicator: Statewide WARN activity remains historically low (13 notices, 1,811 workers in 2026, down 63% from 2025), meaning Louisiana employers should not expect meaningful local talent release from unrelated sector layoffs to ease life sciences hiring pressure.
Potential inflection point: GLP-1-driven manufacturing and quality hiring nationally is pulling CDMO capacity tight; monitor whether preferred outsourcing partners serving Gulf Coast clients begin signaling capacity constraints or price increases tied to this demand surge.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.